Kaartinen Kati, Syrjänen Jaana, Pörsti Ilkka, Hurme Mikko, Harmoinen Aimo, Pasternack Amos, Huhtala Heini, Mustonen Jukka
Kati Kaartinen, Kapteeninkatu 8-10 E 26, FIN-00140 Helsinki, Finland.
Nephrol Dial Transplant. 2008 Apr;23(4):1285-90. doi: 10.1093/ndt/gfm782. Epub 2007 Nov 6.
IgA glomerulonephritis (IgAGN) composes a variable prognosis with 15-40% of the patients eventually progressing to end-stage renal failure. Known risk factors for progressive course of IgAGN include hypertension, proteinuria and renal insufficiency. Although markers of inflammation such as serum or urinary interleukin-6 (IL-6) and serum albumin have predicted progression in some studies, sensitive CRP (hs-CRP) has not been directly linked to the progression of IgAGN.
A total of 174 (70 females) patients were invited for two visits 11 and 16 years (medians) after IgAGN was diagnosed in renal biopsy. All patients had been diagnosed at least 5 years before the first visit. Progressive disease was defined as cystatin-C exceeding normal limits and showing over 20% elevation between the visits, or kidney transplantation or start of dialysis. Cystatin-C and creatinine clearance, serum hs-CRP, s-albumin, s-IL-6 and white blood cell count (WBC) were available for analysis from 118 patients.
IgAGN was progressive in 19.5% of the patients on the second visit. Hs-CRP, s-albumin and WBC of the first visit were significantly associated with the progression of IgAGN (P = 0.014; P = 0.0001; P = 0.023, respectively). S-IL-6 was not associated with the progression. All inflammatory variables correlated significantly with the concurrent level of kidney function. Possible study limitations are the relatively low number of outcomes in the study groups, and the lack of generally accepted definitions for disease progression.
Our results suggest that inflammatory markers hs-CRP, s-albumin and WBC are associated with the progression of IgAGN.
IgA 肾病(IgAGN)的预后各不相同,15% - 40%的患者最终会进展至终末期肾衰竭。IgAGN 进展过程中的已知风险因素包括高血压、蛋白尿和肾功能不全。尽管在一些研究中,炎症标志物如血清或尿液白细胞介素 - 6(IL - 6)和血清白蛋白可预测疾病进展,但超敏 CRP(hs - CRP)与 IgAGN 的进展并无直接关联。
在肾活检确诊 IgAGN 后的 11 年和 16 年(中位数),共邀请了 174 名患者(70 名女性)进行两次随访。所有患者在首次随访前至少已确诊 5 年。疾病进展定义为胱抑素 - C 超过正常范围且两次随访间升高超过 20%,或进行肾移植或开始透析。118 名患者的胱抑素 - C、肌酐清除率、血清 hs - CRP、血清白蛋白、血清 IL - 6 和白细胞计数(WBC)可供分析。
第二次随访时,19.5%的患者 IgAGN 出现进展。首次随访时的 hs - CRP、血清白蛋白和 WBC 与 IgAGN 的进展显著相关(P 值分别为 0.014、0.0001、0.023)。血清 IL - 6 与进展无关。所有炎症变量均与同期肾功能水平显著相关。本研究可能的局限性在于研究组中的结局数量相对较少,且缺乏关于疾病进展的普遍接受的定义。
我们的结果表明,炎症标志物 hs - CRP、血清白蛋白和 WBC 与 IgAGN 的进展相关。